Cargando…

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody

Anifrolumab (anifrolumab) is an antagonist human monoclonal antibody that targets interferon α receptor 1 (IFNAR1). Anifrolumab has been developed to treat autoimmune diseases and is currently in clinical trials. To decipher the molecular basis of its mechanism of action, we engaged in multiple epit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Li, Oganesyan, Vaheh, Wu, Herren, Dall’Acqua, William F, Damschroder, Melissa M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622752/ https://www.ncbi.nlm.nih.gov/pubmed/25606664 http://dx.doi.org/10.1080/19420862.2015.1007810

Ejemplares similares

Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon α-2A
por: Oganesyan, Vaheh, et al.
Publicado: (2008)

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
por: Peng, Li, et al.
Publicado: (2015)

Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

Mechanisms of Neutralization of a Human Anti-α-toxin Antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2014)

Molecular basis for the mechanism of action of an anti-TACE antibody
por: Peng, Li, et al.
Publicado: (2016)

Structural characterization of a human Fc fragment engineered for lack of effector functions
por: Oganesyan, Vaheh, et al.
Publicado: (2008)

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2018)

Long-acting antibody ligand mimetics for HER4-selective agonism
por: Shan, Lu, et al.
Publicado: (2020)

Generation and Characterization of an IgG4 Monomeric Fc Platform
por: Shan, Lu, et al.
Publicado: (2016)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

Insights into the molecular basis of a bispecific antibody's target selectivity
por: Mazor, Yariv, et al.
Publicado: (2015)

Bi-Epitope SPR Surfaces: A Solution to Develop Robust Immunoassays
por: Peng, Li, et al.
Publicado: (2014)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance
por: Shan, Lu, et al.
Publicado: (2021)

Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
por: Geoghegan, James C., et al.
Publicado: (2016)

Structural insights into the interaction of human IgG1 with FcγRI: no direct role of glycans in binding
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

Improving target cell specificity using a novel monovalent bispecific IgG design
por: Mazor, Yariv, et al.
Publicado: (2015)

Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy
por: Varkey, Reena, et al.
Publicado: (2019)

Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval
por: Loncharich, Michael F., et al.
Publicado: (2022)

Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen
por: Wang, Bo, et al.
Publicado: (2019)

The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
por: Peng, Li, et al.
Publicado: (2012)

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
por: Mazor, Yariv, et al.
Publicado: (2017)

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
por: Casey, Kerry A, et al.
Publicado: (2018)

Long-term anifrolumab safe in SLE
por: McHugh, Jessica
Publicado: (2023)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Anifrolumab for Adolescent Discoid Lupus Erythematosus
por: Shaw, Katharina S., et al.
Publicado: (2023)

A case of Rowell syndrome with excellent improvement following anifrolumab
por: Shope, Chelsea, et al.
Publicado: (2022)

Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models
por: Allen, Kevin L., et al.
Publicado: (2020)

Correction: Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models
por: Allen, Kevin L., et al.
Publicado: (2021)

Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
Publicado: (2018)

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
por: Jayne, David, et al.
Publicado: (2022)

Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA
por: Wang, Qun, et al.
Publicado: (2017)

Alopecia secondary to severe discoid lupus responding to anifrolumab
por: Han, Shannon, et al.
Publicado: (2023)

Enhancement of Immune Effector Functions by Modulating IgG’s Intrinsic Affinity for Target Antigen
por: Mazor, Yariv, et al.
Publicado: (2016)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2021)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
por: Almquist, Joachim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7dn7nqdsbqr6m5sfl0ogfbv286